Tollovir™: 3CL Protease Inhibitor
A highly potent 3CL protease inhibitor as a COVID-19 pharmaceutical
Phase 2 Clinical Stage 3CL Protease Inhibitor for Hospitalized Patients
Todos is developing a more concentrated version of Tollovid using a proprietary blend of botanical extracts with an active chemical ingredient that limits replication of coronaviruses. Todos is currently supporting randomized, placebo-controlled clinical trials managed by JV partner NLC Pharma in Israel. Tollovir is the result of over 15 years of development and an investment of over $18M to date.
Learn More About This Clinical-Stage 3CL Protease Inhibitor